Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228
Paul K. Paik, Pang‐Dian Fan, Besnik Qeriqi, Azadeh Namakydoust, Bobby Daly, Linda S. Ahn, Rachel Kim, Andrew J. Plodkowski, Ai Ni, Jason C. Chang, Rachel Fanaroff, Marc Ladanyi, Elisa de Stanchina, Charles M. Rudin
Topics & Concepts
MedicineKRASOncologyKEAP1GlutaminaseTargeted therapyCancer researchInternal medicineCancerGeneColorectal cancerTranscription factorReceptorBiologyGeneticsGlutamate receptorGenomics, phytochemicals, and oxidative stressLung Cancer Treatments and MutationsProtein Tyrosine Phosphatases